Related Experiment Video
Updated: May 24, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
Amantadine-induced myoclonus in a patient with progressive supranuclear palsy
Alison Jane Yarnall1, David John Burn
1Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK. alison.yarnall@ncl.ac.uk
Abstract:
Progressive supranuclear palsy (PSP) is a tauopathy that generally results in a hypokinetic disorder. Treatment is largely symptomatic, with some small studies indicating a benefit with dopaminergic therapy. Myoclonus is a hyperkinetic disorder that can be seen as part of later stage Parkinson's disease and in multiple system atrophy, but is rarely seen in PSP. Here we report a case of myoclonus precipitated by amantadine in a patient with PSP.
More Related Videos
07:35Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Alterations in Muscle Tone lll
Huntington Disease l: Introduction
Alterations in Muscle Tone ll
Parkinson Disease l: Introduction